Tag Archives: Metadoxine

Alcobra’s Selective Inattention

Last week, in the October issue of NeuroPerspective, which covered ADHD, we noted the delay in Alcobra’s disclosure of Phase III data for MDX (metadoxine), and stated “ our suspicion is that the analysis of the primary and secondary endpoints … Continue reading

Posted in BioFollies, Biotech | Tagged , , , | 1 Comment